Patents Assigned to Alnylam Pharmaceuticals
  • ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230138507
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting an alpha-2A adrenergic receptor (ADRA2A) gene, as well as methods of inhibiting expression of an ADRA2A gene and methods of treating subjects having an ADRA2A-associated disease or disorder, e.g., a primary tauopathy or Alzheimer's disease, using such dsRNAi agents and compositions.
    Type: Application
    Filed: April 1, 2021
    Publication date: May 4, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: BRET L. BOSTWICK, JAMES D. MCININCH, ADAM CASTORENO
  • COMPOSITIONS AND METHODS FOR SILENCING VEGF-A EXPRESSION
    Publication number: 20230136787
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting VEGF-A, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of VEGF-A.
    Type: Application
    Filed: February 9, 2021
    Publication date: May 4, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: JAMES D. MCININCH, MARK KEATING, MARK K. SCHLEGEL, ADAM CASTORENO, VASANT R. JADHAV, CHARALAMBOS KAITTANIS, ELENA CASTELLANOS-RIZALDOS, BHAUMIK A. PANDYA
  • Fc FRAGMENT OF IgG RECEPTOR AND TRANSPORTER (FCGRT) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230126881
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting a Fc fragment of IgG receptor and transporter (FCGRT) gene encoding neonatal Fc receptor (FcRn). The invention also relates to methods of using such RNAi agents to inhibit expression of the FCGRT gene or production of the FcRn protein and to methods of preventing and treating a hepatotoxicity-associated disorder, e.g., alcoholic hepatitis, iron overload, and hepatocellular carcinoma.
    Type: Application
    Filed: March 26, 2021
    Publication date: April 27, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: AIMEE DEATON, MARGARET PARKER, LEILA NOETZLI, JAMES D. MCININCH
  • MANNAN BINDING LECTIN SERINE PEPTIDASE 2 (MASP2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230125933
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the mannan binding lectin serine peptidase 2 gene (MASP2). The invention also relates to methods of using such RNAi agents to inhibit expression of a MASP2 gene and to methods of preventing and treating a MASP2-associated disorders, e.g., arthritis, IgA nephropathy, thrombotic microangiopathy, diabetic nephropathy and membranous nephropathy.
    Type: Application
    Filed: February 18, 2021
    Publication date: April 27, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: JAMES D. MCININCH, ANNA BORODOVSKY
  • LEUCINE-RICH REPEAT KINASE 2 (LRRK2) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230126233
    Abstract: The disclosure relates to double stranded ribonucleic acid (dsRNAi) agents and compositions targeting a leucine-rich repeat kinase 2 (LRRK2) gene, as well as methods of inhibiting expression of a LRRK2 gene and methods of treating subjects having a LRRK2-associated disease or disorder, e.g., Parkinson's disease, using such dsRNAi agents and compositions.
    Type: Application
    Filed: January 22, 2021
    Publication date: April 27, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: JAMES D. MCININCH, JASON A. GILBERT, ADAM CASTORENO, LAN THI HOANG DANG, SARAH LEBLANC, HAIYAN PENG, CHARALAMBOS KAITTANIS, MANGALA MEENAKSHI SOUNDARAPANDIAN
  • Biodegradable lipids for the delivery of active agents
    Patent number: 11633480
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: April 25, 2023
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Biodegradable lipids for the delivery of active agents
    Patent number: 11633479
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: April 25, 2023
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER
    Publication number: 20230104125
    Abstract: The invention relates to methods of inhibiting the expression of a PCSK9 gene in a subject, as well as therapeutic and prophylactic methods for treating subjects having a lipid disorder, such as a hyperlipidemia using RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene.
    Type: Application
    Filed: March 31, 2022
    Publication date: April 6, 2023
    Applicants: Alnylam Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc.
    Inventor: Kevin Fitzgerald
  • KISSPEPTIN 1 (KISS1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230101828
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the KISS1 gene. The invention also relates to methods of using such RNAi agents to inhibit expression of a KISS1 gene and to methods of preventing and treating a deficiency in glycemic control, e.g., type 2 diabetes mellitus (T2DM).
    Type: Application
    Filed: June 10, 2022
    Publication date: March 30, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Mangala Meenakshi Soundarapandian, Gregory Hinkle
  • Biodegradable lipids for the delivery of active agents
    Patent number: 11612657
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: March 28, 2023
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
    Patent number: 11613751
    Abstract: The present invention relates to RNAi agents, e.g., double stranded RNA (dsRNA) agents, targeting the Angiopoietin-like 3 (ANGPTL3) gene. The invention also relates to methods of using such RNAi agents to inhibit expression of an ANGPTL3 gene and to methods of preventing and treating an ANGPTL3-associated disorder, e.g., a disorder of lipid metabolism, such as hyperlipidemia or hypertriglyceridemia.
    Type: Grant
    Filed: March 8, 2022
    Date of Patent: March 28, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Lucas D. BonDurant, Mark K. Schlegel, Jeffrey Zuber, Lauren Blair Woods, Tyler Chickering
  • Chirally-enriched double-stranded RNA agents
    Patent number: 11597932
    Abstract: The present invention relates to a chirally-modified dsRNA agent capable of inhibiting the expression of a target gene. The sense and antisense strands of chirally-modified dsRNA agent independently or in combination comprises one or more site specific-site specific/position specific, chirally-modified internucleotide linkages.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: March 7, 2023
    Assignee: Alnylam Pharmaceuticals, Inc.
    Inventors: Muthiah Manoharan, Nate Taneja, Hartmut Ingo Jahns, Shigeo Matsuda, Klaus Charisse, Guo He, Jayaprakash K. Nair, Christopher Brown, Mark K. Schlegel, Vasant Jadhav, Martin Maier
  • Biodegradable lipids for the delivery of active agents
    Patent number: 11590229
    Abstract: The present invention relates to a cationic lipid having one or more biodegradable groups located in a lipidic moiety (e.g., a hydrophobic chain) of the cationic lipid. These cationic lipids may be incorporated into a lipid particle for delivering an active agent, such as a nucleic acid. The invention also relates to lipid particles comprising a neutral lipid, a lipid capable of reducing aggregation, a cationic lipid of the present invention, and optionally, a sterol. The lipid particle may further include a therapeutic agent such as a nucleic acid.
    Type: Grant
    Filed: February 14, 2022
    Date of Patent: February 28, 2023
    Assignee: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Martin Maier, Muthusamy Jayaraman, Akin Akinc, Shigeo Matsuda, Pachamuthu Kandasamy, Kallanthottathil G. Rajeev, Muthiah Manoharan
  • ATAXIN3 (ATXN3) RNAI AGENT COMPOSITIONS AND METHODS OF USE THEREOF
    Publication number: 20230056569
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) agents and compositions targeting the ATXN3 gene, as well as methods of inhibiting expression of an APP gene and methods of treating subjects having an ATXN3-associated disease or disorder, such as SCA3, using such dsRNA agents and compositions.
    Type: Application
    Filed: November 20, 2020
    Publication date: February 23, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: ADAM CASTORENO, ELANE FISHILEVICH, JASON A. GILBERT, CHARALAMBOS KAITTANIS, JAMES D. MCININCH, STUART MILSTEIN, MARK K. SCHLEGEL
  • COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF MUTANT EGFR GENE
    Publication number: 20230053332
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a mutant Epidermal Growth Factor Receptor (EGFR), and methods of using the dsRNA to inhibit expression of mutant EGFR.
    Type: Application
    Filed: April 29, 2022
    Publication date: February 23, 2023
    Applicants: ALNYLAM PHARMACEUTICALS, INC., LUDWIG INSTITUTE FOR CANCER RESEARCH LTD.
    Inventors: DINAH SAH, PAMELA TAN, WEBSTER CAVENEE, FRANK FURNARI, MARIA DEL MAR INDA PEREZ, RUDY BONAVIA
  • MODIFIED DOUBLE STRANDED OLIGONUCLEOTIDE
    Publication number: 20230049529
    Abstract: The disclosure is directed to dual variable domain immunoglobulin double-stranded RNA conjugates that are advantageous for inhibition of target gene expression, as well as compositions suitable for therapeutic use. The dual variable domain immunoglobulin comprises a first variable domain that binds to a binding target, and a second variable domain that comprises a reactive residue, where the linker is covalently conjugated to the reactive residue. The dsRNA is linked to the linker and is capable of inhibiting the expression of the target gene by RNA interference. The disclosure also provides pharmaceutical compositions comprising these conjugate and methods of inhibiting the expression of a target gene by administering these conjugates, e.g., for the treatment of various disease conditions.
    Type: Application
    Filed: June 18, 2020
    Publication date: February 16, 2023
    Applicants: Alnylam Pharmaceuticals, Inc., THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Alexander V. KEL'IN, Alex R. NANNA, Christopher RADER, Christopher THEILE, Justin PIERSON, Kevin FITZGERALD, Zhi Xiang VOO
  • COMPOSITIONS AND METHODS FOR SILENCING DNAJB1-PRKACA FUSION GENE EXPRESSION
    Publication number: 20230040920
    Abstract: The disclosure relates to double-stranded ribonucleic acid (dsRNA) compositions targeting the DNAJB 1-PRKAC A fusion gene, and methods of using such dsRNA compositions to alter (e.g., inhibit) expression of DNAJB 1-PRKAC A fusion.
    Type: Application
    Filed: October 30, 2020
    Publication date: February 9, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: LEILA NOETZLI, HO-CHOU TU, PATRICK HASLETT, JAMES MCININCH
  • SYNTHESIS OF 3 -RNA OLIGONUCLEOTIDES
    Publication number: 20230021879
    Abstract: Provided is a method of treating cancer cells localized in the lung by administering to such patients a therapeutically effective amount of a liposomal annamycin formulation (L-Ann).
    Type: Application
    Filed: November 23, 2020
    Publication date: January 26, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Jayaprakash K. NAIR, Juan C. SALINAS, John Frederick BRIONES, Mark K. SCHLEGEL, Shigeo MATSUDA, Alexander V. KEL'IN, Ligang ZHANG, Martin A. MAIER
  • TUNABLE REVERSIR TM COMPOUNDS
    Publication number: 20230029227
    Abstract: The present invention relates, in general to agents that modulate the pharmacological activity of siRNAs. In addition, the invention relates generally to methods and systems for use in assessing the efficacy and safety of a pharmaceutical composition for use in the treatment or prophylaxis of a disease.
    Type: Application
    Filed: January 25, 2022
    Publication date: January 26, 2023
    Applicant: ALNYLAM PHARMACEUTICALS, INC.
    Inventors: Ivan ZLATEV, Adam CASTORENO, Martin MAIER, Vasant JADHAV, Jae KIM, Pushkal GARG
  • RNAI AGENTS, COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING TRANSTHYRETIN (TTR) ASSOCIATED DISEASES
    Publication number: 20230010288
    Abstract: The present invention provides RNAi agents, e.g., double stranded RNAi agents, that target the transthyretin (TTR) gene and methods of using such RNAi agents for treating or preventing TTR-associated diseases.
    Type: Application
    Filed: July 9, 2021
    Publication date: January 12, 2023
    Applicant: Alnylam Pharmaceuticals, Inc.
    Inventors: Kallanthottathil G. Rajeev, Tracy Zimmermann, Muthiah Manoharan, Martin A. Maier, Satyanarayana Kuchimanchi, Klaus Charisse